| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T280 |
0-136 |
Sentence |
denotes |
Ke Hu et al. conducted a prospective multicenter open-label randomized controlled trial on LHQWC capsule in confirmed cases of COVID-19. |
| T281 |
137-281 |
Sentence |
denotes |
Patients (284) were randomized to receive usual treatment alone or in combination with LHQWC capsules (four capsules, thrice daily) for 14 days. |
| T282 |
282-363 |
Sentence |
denotes |
The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. |
| T283 |
364-500 |
Sentence |
denotes |
The recovery rate was significantly higher in the combined treatment group compared with the control group (91.5% vs. 82.4%, p = 0.022). |
| T284 |
501-598 |
Sentence |
denotes |
The median time to symptom recovery was markedly shorter in the combined treatment group (median: |
| T285 |
599-625 |
Sentence |
denotes |
7 vs. 10 days, p < 0.001). |
| T286 |
626-799 |
Sentence |
denotes |
Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in the combined treatment group (all p < 0.001). |
| T287 |
800-994 |
Sentence |
denotes |
The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p < 0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) were also higher in the combined treatment group. |
| T288 |
995-1111 |
Sentence |
denotes |
However, the two groups did not differ in the rate of conversion to severe cases or viral assay findings (p > 0.05). |
| T289 |
1112-1170 |
Sentence |
denotes |
No serious adverse events were reported (Hu et al., 2020). |
